Bydureon and Synjardy drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Bydureon (exenatide synthetic) and Synjardy (empagliflozin; metformin hydrochloride). Common drug interactions include nasal congestion among females and injection site pain among males.

The phase IV clinical study analyzes what interactions people have when they take Bydureon and Synjardy. It is created by eHealthMe based on reports of 27 people who take the same drugs from the FDA, and is updated regularly.

What is Bydureon?

Bydureon has active ingredients of exenatide synthetic. It is often used in type 2 diabetes. eHealthMe is studying from 24,309 Bydureon users. Check the latest studies of Bydureon.

What is Synjardy?

Synjardy has active ingredients of empagliflozin; metformin hydrochloride. eHealthMe is studying from 2,928 Synjardy users. Check the latest studies of Synjardy.



On Jul, 15, 2026

27 people who take Bydureon and Synjardy together, and have interactions are studied.

Bydureon and Synjardy drug interactions.

What are the common drug interactions of Bydureon and Synjardy, by gender? *:

female:

  1. Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
  2. Sinusitis (inflammation of sinus)
  3. Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)
  4. Injection site mass
  5. Blood glucose increased
  6. Vomiting
  7. Amputation
  8. Blood cholesterol increased
  9. Hypertension (high blood pressure)
  10. Injection site bruising

male:

  1. Injection site pain
  2. Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
  3. Alcohol interaction
  4. Arteriosclerosis coronary artery (thickening and hardening of arteries- coronary artery)
  5. Benign prostatic hyperplasia (benign enlargement of the prostate)
  6. Blood glucose increased
  7. Diabetes mellitus inadequate control
  8. Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)
  9. Diverticulum intestinal (a pouch that is attached to the first part of the small intestine)
  10. Erythema (redness of the skin)

What are the common drug interactions of Bydureon and Synjardy, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Injection site mass
  2. Injection site pruritus (severe itching at injection site)

40-49:

  1. Hypokalaemia (low potassium)
  2. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
  3. Necrotising fasciitis (an uncommon life-threatening soft-tissue infection)
  4. Sepsis (a severe blood infection that can lead to organ failure and death)
  5. Transaminases increased

50-59:

  1. Blood cholesterol increased
  2. Hypertension (high blood pressure)
  3. Injection site bruising
  4. Injection site mass
  5. Abdominal discomfort
  6. Abdominal pain upper
  7. Alcohol interaction
  8. Angina pectoris (chest pain due to ischemia of the heart muscle)
  9. Anxiety
  10. Arrhythmia (irregular heartbeat)

60+:

  1. Injection site pain
  2. Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
  3. Amputation
  4. Pain in extremity
  5. Skin ulcer
  6. Tachycardia (a heart rate that exceeds the range of 100 beats/min)
  7. Arterial disorder
  8. Arteriosclerosis coronary artery (thickening and hardening of arteries- coronary artery)
  9. Benign prostatic hyperplasia (benign enlargement of the prostate)
  10. Confusional state

What are the existing conditions these people have? *

  1. Diabetes: 7 people, 25.93%
  2. High Blood Pressure: 5 people, 18.52%
  3. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 3 people, 11.11%
  4. Weight Loss: 2 people, 7.41%
  5. High Blood Cholesterol: 2 people, 7.41%
  6. Dyslipidaemia (abnormal amount of lipids): 2 people, 7.41%

* Approximation only. Some reports may have incomplete information.

Do you take Bydureon and Synjardy?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Bydureon and Synjardy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Bydureon:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Synjardy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Bydureon and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Synjardy and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on exenatide synthetic and empagliflozin; metformin hydrochloride (the active ingredients of Bydureon and Synjardy, respectively), and Bydureon and Synjardy (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: